Ad Board Preread
Please familiarize yourself with the content listed below prior to our Ad Board.
Overview
Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.
MydCombi: High-Precision Microdosing
High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine, Therapeutic Delivery 2018
MydCombi: MIST Pooled Data
Mydriasis with micro-array print touch-free tropicamide-phenylephrine fixed combination MIST: pooled randomized Phase III trials, Therapeutic Delivery, 2021
MydCombi: Microdosing vs Eye Drops
Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper Therapeutic Delivery, 2016
MydCombi: SPEED Study
Evaluation of 2 mydriatic dosing regimens delivered by micro-array print technology for comparison of pupil dilation speed
MicroLine: VISION-1
Clinical Trial Design and Results
MicroLine: VISION 2
Clinical Trial Design
Glaucoma: Latanoprost Microdose
Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of 0.4 μg Clinical Ophthalmology 2018
Preservative Free: BAK Study
In Vitro Study
MedTech Outlook
Top 10 Vision Care Devices and Equipment Companies – 2022